Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 7/20 | 0.46 |
| ▸ | BACE1 | P56817 | 7/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.44 |
| ▸ | PRKDC | P78527 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030873 | 0.77 | HTT (0.54) | ACHEBACE1PDE10APDGFRBPRKDC | |
| SCHEMBL5518977 | 0.75 | ACHE (0.76) | ACHEBACE1PDE10AAURKAENPP1 | |
| SCHEMBL4779400 | 0.74 | ACHE (0.61) | ACHEBACE1PDE10APDGFRBAURKA | |
| SCHEMBL3873291 | 0.74 | ACHE (0.78) | ACHEBACE1PDE10AAURKAENPP1 | |
| SCHEMBL4779574 | 0.72 | ACHE (0.63) | ACHEBACE1PDE10APDGFRBAURKA | |
| SCHEMBL25656113 | 0.70 | PRKDC (0.52) | ACHEBACE1PDE10AENPP1PRKDC | |
| SCHEMBL15314918 | 0.70 | PRKDC (0.52) | ACHEBACE1PDE10AENPP1PRKDC | |
| SCHEMBL25656111 | 0.70 | ENPP1 (0.64) | ACHEBACE1PDE10APDGFRBAURKA | |
| SCHEMBL4726710 | 0.69 | ENPP1 (0.65) | ACHEBACE1PDE10APDGFRBAURKA | |
| SCHEMBL29357509 | 0.69 | ACHE (0.66) | ACHEBACE1PDE10AAURKAENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ACHE 3684/4885BACE1 1090/4885PDE10A 3998/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | ACHE 4285/4885BACE1 483/4885PDE10A 3299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.